Grant: Collaborative Research and Development Grants
Simon Fraser University
$24,500.00
Enhancement of immunogenicity by increased retention of antigenic proteins to injection sites and multimerization
FY 2018-19
Summary
Protection from infectious diseases by vaccines is the most cost effective measure to decrease the impact of*many bacterial and viral diseases. For vaccines their safety is the paramount importance. Thus, most new*vaccines for human use are developed as inactivated or component vaccines. The difficulty in the protein-based*component vaccines is their relatively weak immunological stimulation. To overcome this problem various*adjuvants that potentially enhance the antigenic stimulation are tested. iProgen has developed new technologies*that enhance the retention of proteins to animal tissues and multimerize proteins with minimal modification.*We thought the increased retention and multimerization of antigenic molecules might help enhance the*immune stimulation through the similar mechanism as some of the commonly used adjuvant.*The proposed study is to test if such modifications of an antigenic protein may help enhance the immune*stimulation in animal models. We are testing the potentials in both systemic and mucosal stimulations. We will*use Green Fluorescent Protein (GFP) as the test antigenic protein. GFP is modified to stay in the injected site*by the new technology developed by iProgen. In the first experiment the modified and unmodified GFPs will*be inoculated to mice intramuscularly and the development of specific antibody to GFP is monitored. Whether*conventional alum adjuvant co-operatively works or not will also be investigated. In the second experiment the*modified and unmodified GFP will be applied to nasal mucosal surface in the presence or absence of a mucosal*adjuvant, FSL-1. The induction of specific antibodies on the mucosal surface will be monitored in feces and*nasal wash of the inoculated mice. If successful, this technology would be further tested whether modified viral*proteins can induce protective immunity to viral diseases in animal models. Ultimately, we are hoping this*technology will help develop new safer, more efficacious and less expensive vaccines for various infectious*diseases.
Program
Collaborative Research and Development Grants
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
531113-2018
Name nom
Niikura, Masahiro
Department département
Health Sciences, Faculty of
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
24500
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
1
Application title
Enhancement of immunogenicity by increased retention of antigenic proteins to injection sites and multimerization
Keyword
NSERC
Application summary
Protection from infectious diseases by vaccines is the most cost effective measure to decrease the impact of*many bacterial and viral diseases. For vaccines their safety is the paramount importance. Thus, most new*vaccines for human use are developed as inactivated or component vaccines. The difficulty in the protein-based*component vaccines is their relatively weak immunological stimulation. To overcome this problem various*adjuvants that potentially enhance the antigenic stimulation are tested. iProgen has developed new technologies*that enhance the retention of proteins to animal tissues and multimerize proteins with minimal modification.*We thought the increased retention and multimerization of antigenic molecules might help enhance the*immune stimulation through the similar mechanism as some of the commonly used adjuvant.*The proposed study is to test if such modifications of an antigenic protein may help enhance the immune*stimulation in animal models. We are testing the potentials in both systemic and mucosal stimulations. We will*use Green Fluorescent Protein (GFP) as the test antigenic protein. GFP is modified to stay in the injected site*by the new technology developed by iProgen. In the first experiment the modified and unmodified GFPs will*be inoculated to mice intramuscularly and the development of specific antibody to GFP is monitored. Whether*conventional alum adjuvant co-operatively works or not will also be investigated. In the second experiment the*modified and unmodified GFP will be applied to nasal mucosal surface in the presence or absence of a mucosal*adjuvant, FSL-1. The induction of specific antibodies on the mucosal surface will be monitored in feces and*nasal wash of the inoculated mice. If successful, this technology would be further tested whether modified viral*proteins can induce protective immunity to viral diseases in animal models. Ultimately, we are hoping this*technology will help develop new safer, more efficacious and less expensive vaccines for various infectious*diseases.